USE OF AROMATIC DIAMINES FOR THE TREATMENT OF ANGINA PECTORIS, AND DIAMINES THEREFOR

Abstract: A method of treatment or prophylaxis of angina in mam­ mals, such as humans, which comprises the administration to the sufferer of an effective amount of a compound of for­ mula (I), or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing: wherein A R₁ and R₄ are independently phenyl optionally substitu­ ted by one, two or three of halogen, trifluoromethyl, C₁ ₄ alkoxy, C₁ ₄ alkyl, cyano, hydroxy, nitro, NR₅R₆ or O₂SNR₅R₆ wherein R₅ and R₆ are independently hydrogen or C₁ ₆ alkyl or together are C₃₋₆ polymethylene or disubstituted at adjacent carbon atoms by C₁₋₂ alkylenedioxy and optionally further substituted by one of the above groups; R₂ is selected from (CH₂)₂ CN where z is 0 or an integer from 1 to 4, C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl C₁₋₄ alkyl, pyridyl, pyridyl C₁₋₄ alkyl, COR₇, COCH₂COR₇, SO₂R₇, CO₂R₇, CONHR₇ and CSNHR₇, where R₇ is selected from C₃₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁ ₄ alkyl, phenyl and phenyl C₁₋₄ alkyl, any alkyl moiety in R₇ opti­ onally substituted by hydroxy or C₁₋₄ alkanoyloxy, any pyridyl or phenyl moiety in R₂ optionally substituted as defined for R¹ and R⁴ and any cycloalkyl moiety in R₂ optionally substituted by one or two C₁₋₄ alkyl groups; R₃ is hydrogen or C₁ ₄ alkyl; A represents C₂₋₅ alkylene; and B represents C₁ ₄ alkylene.

Description: The present invention relates to a method of treatment or prophylaxis of angina pectoris in mammals, and to novel compounds useful in such a method. British Patent 862467 discloses a class of compounds of formula (A): in which R is hydrogen or halogen or a lower alkoxy, hydroxy, lower alkanoyloxy, lower alkyl, nitro, amino or lower alkanoylamino radical, R b is hydrogen or halogen or a lower alkyl, lower alkoxy, hydroxy or lower alkanoyloxy radical, R a and R c are lower alkyl radicals, X¹ is a divalent hydrocarbon radical of 1-4 carbon atoms, and wherein said lower radicals contain not more than six carbon atoms, and where A a and B a can each be a hydrogen atom, a methyl group or ethyl group with the proviso that together they may not contain more than two carbon atoms, and acid addition salts thereof. The compounds are described as active as analgesics. Compounds specifically disclosed in the patent include those where [R, X¹, R a , A a , B a , R c , R b ] take the following combinations of values: [H, CH₂, CH₃, H, H, nC₃H₇, H], [H, CH₂, CH₃, H, H, iC₃H₇, H], [H, (CH₂)₂, CH₃, H, CH₃, nC₃H₇, H], [H, (CH₂)₂, CH₃, CH₃, H, nC₃H₇, H], [H, (CH₂)₂, CH₃, CH₃, H, iC₃H₇, H] and [H, (CH₂)₂, CH₃, CH₃, H, nC₄H₉, H]. In European Journal of Pharmacology, 44(1977) 251-270, Frans G. Van den Brink and Erik J. Lien, a group of compounds are studied in a histaminic and a cholinergic system. The compounds are of formula (B): where the variables [R d , R e , A b , R f , B b , R g ] take the following values: [phenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₃, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, 4-chlorobenzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, 4-chlorophenyl] In Ann. 1st. Super. Sanita 1971, 7 (Pt. 4), 533-9, the compounds where n is 1 or 2, are described as chemical intermediates in the preparation of certain benzodiazepines. GB 1,050,132 describes N,N'-substituted diaminoethane compounds which are described as possessing physiological activity on the heart and the blood circulation. It has been discovered that compounds of formula (1) and pharmaceutical salts thereof: wherein R₁ and R₄ are independently phenyl optionally substituted by one, two or three of halogen, trifluoromethyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, cyano, hydroxy, nitro, NR₅R₆ or O₂SNR₅R₆ wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl or together are C₃₋₆ polymethylene, or disubstituted at adjacent carbon atoms by C₁₋₂ alkylenedioxy and optionally further substituted by one of the above groups; R₂ is selected from (CH₂) z CN where z is O or an integer from 1 to 4 , C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl C₁₋₄ alkyl, pyridyl, pyridyl C₁₋₄ alkyl, COR₇, COCH₂COR₇, SO₂R₇, CO₂R₇, CONHR₇ and CSNHR₇, where R₇ is selected from C₃₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl and phenyl C₁₋₄ alkyl, any alkyl moiety in R₇ optionally substituted by hydroxy or C₁₋₄ alkanoyloxy, any pyridyl or phenyl moiety in R₂ optionally substituted as defined for R₁ and R₄ and any cycloalkyl moiety in R₂ optionally substituted by one or two C₁₋₄ alkyl groups; R₃ is hydrogen or C₁₋₄ alkyl; A represents C₂₋₅ alkylene; and B represents C₁₋₄ alkylene, have been found to possess cardiovascular activity, in particular calcium antagonistic activity which indicates that they are of potential use in the treatment of angina pectoris. An amount effective to treat the disorder hereinbefore described depends on the relative efficacies of the compounds of the formula (1), the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 0.1 to 500 mg for example 2 to 50 mg, of the compound of the invention. Unit doses will normally be administered once or more than once a day, for example 2,3,4,5 or 6 times a day, more usually 2 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 2500 mg, more usually 50 to 2000 mg, for example 10 to 75mg, that is in the range of approximately 0.002 to 35 mg/kg/day, more usually 1 to 30 mg/kg/day, for example 0.15 to 1 mg/kg/day. At the above described dosage range, no toxicological effects are indicated for the compounds of the invention. In such treatment, the compound may be administered by any suitable route, e.g. by the oral, parenteral or topical routes. For such use, the compound will normally be employed in the form of a pharmaceutical composition in association with a human or veterinary pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration. Compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use. Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art. Suitable fillers for use include cellulose, mannitol, on lactose Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. These solid oral compositions may be prepared by conventional methods of blending, filling on tabletting Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, iractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol, preservatives, for example methyl or propyl p -hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents. For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound. For topical administration, the composition may be in the form of a transdermal ointment or patch for systemic delivery of the compound and may be prepared in a conventional manner, for example, as described in the standard textbooks such as 'Dermatological Formulations' - B.W. Barry (Drugs and the Pharmaceutical Sciences - Dekker) or Harrys Cosmeticology (Leonard Hill Books). In addition such compositions may contain further active agents such as anti-hypertensive agents and diuretics. As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned. The invention also provides the use of a compound of formula (I) or a pnarmaceutically acceptable salt thereof, or a solvate of any of the foregoing, for the preparation of a medicament for the treatment or prophylaxis of angina pectoris in mammals. The invention further provides a pharmaceutical composition for use in the treatment or prophylaxis of angina pectoris in mammals, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a solvate or any of the foregoing, and a pharmaceutically acceptable carrier. Such compositions may be prepared in the manner hereinbefore described. In formula (I), it is understood that alkyl and alkylene includes straight- and branched-chain alkyl and alkylene. Suitable values for R₁ and R₄ include phenyl, phenyl di-substituted by methylenedioxy and optionally further substituted by chloro, or phenyl substituted by one, two or three of fluoro, chloro, bromo, trifluoromethyl, methoxy, ethoxy, n - or iso -propoxy, methyl, ethyl, n -or iso -propyl, cyano, hydroxy or amino optionally substituted by one or two methyl groups. R₁ and R₄ are preferably the same group, most preferably 3,4-dimethoxyphenyl. Suitable values for phenyl moieties in R₂ include phenyl, 2-, 3- and 4-nitrophenyl, 3,5-dinitrophenyl, 3-methoxyphenyl, 3-methoxy-6-methylphenyl, 2-trifluoromethylphenyl, 2,4,6-trimethylphenyl, 2,6-dichlorophenyl, 2-chloro-3,4-methylenedioxyphenyl, 4-cyanophenyl, 4-chlorophenyl and 4-methylphenyl. Suitable values for cycloalkyl moieties in R₂ include cyclopentyl, cyclohexyl and menthyl. Suitable values for alkylene moieties in R₂ include -CH₂-, -CH(CH₃)- -CH₂CH₂CH₂- and -CH₂CH₂-. Suitable values for R₂ when alkyl include n-pentyl. Alkyl R₇ in R₂ may be C₄₋₁₂, more preferably C₅₋₁₂ alkyl groups which are preferably straight-chain. Suitable values for alkyl R₇ in R₂ includes n- and iso- C₃H₇, n-C₄H₉, n-C₅H₁₁, nC₆H₁₃, nC₇H₁₅, nC₈H₁₇ and nC₁₁H₂₃. Suitable values for pyridyl moieties in R₂ include 2-pyridyl optionally 3,5-dinitro-substituted. Suitable values for optional substituents on alkyl moieties in R₇ include acetoxy. Suitable values for z in R₂ include 0 or 1. Suitable values for C₁₋₄ alkyl groups in R₂ include methyl and ethyl. Suitable values for R₃ include hydrogen, methyl, ethyl, n - and iso -propyl, and n , iso -, sec - and t -butyl. Preferably R₃ is methyl. Suitable values for A and B include -(CH₂)₂- and -(CH₂)₃-. There is a sub-group of compounds within formula (I) of formula (II): wherein: R₁, R₃ and R₄ are as defined in formula (I); and R₂¹ is (CH₂) z CN, C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl or phenyl C₁₋₄ alkyl wherein z is as defined in formula (I) and any phenyl, alkyl, or cycloalkyl moieties in R₂¹ are optionally substituted as defined for corresponding variables R₂ in formula (I). Suitable and preferred values for R₂¹,R₁,R₃ and R₄ are as described for the corresponding variables under formula (I). A preferred value for R₁ and R₄ is 3,4-dimethoxyphenyl. There is another group of compounds within formula (I) of formula (IIa): wherein R₂² is COR₇ where R₇ is as defined in formula (I), and the remaining variables are as defined in formula (I). There is further group of compounds within formula (I) of formula (IIb): wherein R₂³ is CO₂R₇ or SO₂R₇ where R₇ is as defined in formula (I), and the remaining variables are as defined in formula (I). There is another group of compounds within formula (I) of formula (IIc): wherein R₂⁴ is CONHR₇ or CSNHR₇ where R₇ is as defined in formula (I), and the remaining variables are as defined in formula (I). Suitable and preferred values for the variables of formulae (IIa), (IIb) and (IIc) are as described for the corresponding variables under formula (II). It will of course be realized that the compounds of formula (I) possess two chiral centres and therefore exist in more than one stereoisomeric form. The invention extends to any of the stereoisometric forms, including enantiomers of the compounds of formula (I) and to mixtures thereof, including racemates. The different stereoisomeric forms may be separated or resolved one from the other by the usual methods or any given isomer may be obtained by stereospecific or asymmetric syntheses. The pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α-keto-glutaric, α-glycerophosphoric, and glucose-1-phosphoric acids. Preferably the acid addition salt is a hydrochloride. Pharmaceutically acceptable salts also include quaternary salts. Examples of quaternary salts include such compounds quaternised by compounds such as R₈-T wherein R₈ is C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or C₅₋₇ cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of R₈ include methyl, ethyl and n - and iso - propyl; and benzyl and phenethyl. Suitable T include halide such as chloride, bromide and iodide. Pharmaceutically acceptable salts also include pharmaceutically acceptable N-oxides. The compounds of the formula (I) and their pharmaceutically acceptable salts may also form solvates with pharmaceutically acceptable solvates. It will also be realised that salts of the compounds of the formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the preparation of pharmaceutically acceptable salts of compounds of the formula (I) or the compounds of the formula (I) themselves. The invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing, with the proviso that the variables [R₁, R₂, A, R₃, B, R₄] do not take the following combinations of values: [phenyl, CO n C₃H₇, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, COiC₃H₇, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, COnC₃H₇, CH(CH₃)CH₂, CH₃, (CH₂)₂, phenyl] [phenyl, COnC₃H₇, CH₂CH(CH₃), CH₃, (CH₂)₂, phenyl] [phenyl, COiC₃H₇, CH₂CH(CH₃), CH₃, (CH₂)₂, phenyl] [phenyl, COnC₄H₉, CH₂CH(CH₃), CH₃,(CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₃, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, 4-chlorobenzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, 4-chlorophenyl] for use as an active therapeutic substance, and particularly for the treatment or prophylaxis of angina pectoris. The class of compounds as just defined will be referred to hereinafter as compounds of formula (IA). The invention also provides a pharmaceutical composition comprising a compound of formula (IA) and a pharmaceutically acceptable carrier. In another aspect the invention provides a compound of formula (IA) with the proviso that the variables [R₁, R₂, A, R₃, B, R₄] do not take the following combinations of values: [3,4-dimethoxyphenyl, C₂H₅, (CH₂)₂, H, (CH₂)₂, phenyl] [3,4-dimethoxyphenyl, C₂H₅, (CH₂)₂, H, CH₂, phenyl] The class of compounds as just defined will be referred to hereinafter as compounds of formula (IB). Suitable and preferred values for variables in formula (IB) are as defined for the corresponding variables in formula (I). In one sub-group of the formula (IB), R₁ and R₄ are independently phenyl substituted as defined in formula (I). In another sub-group of the formula (IB), R₂ is COR₇ where R₇ is phenyl or phenyl C₁₋₄ alkyl, the phenyl moiety optionally substituted as defined for R₁ and R₄. In a further subgroup of formula (IB), R₂ is C₃₋₁₂ alkyl. In another subgroup of formula (IB), R₁ and R₄ are independently phenyl substituted by one, two or three of halogen, trifluoromethyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, cyano, hydroxy, nitro, NR₅R₆ or O₂SNR₅R₆ wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl or together are C₃₋₆ polymethylene, or disubstituted at adjacent carbon atoms by C₁₋₂ alkylenedioxy; R₂ is selected from (CH₂) z CN where z is O or an integer from 1 to 4, C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl C₁₋₄ alkyl, COR₇, SO₂R₇, CO₂R₇, CONHR₇ and CSNHR₇, where R₇ is selected from C₃₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl and phenyl C₁₋₄ alkyl, any phenyl moiety in R₂ optionally substituted as defined for R₁ and R₄; R₃ is hydrogen or C₁₋₄ alkyl; A represents C₂₋₅ alkylene; and B represents C₁₋₄ alkylene. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof comprises reacting together R₁₀X and YR₁₁ wherein one of X and Y is a leaving group or aldehyde or ketone function and the other is a nitrogen nucleophile, the nitrogen nucleophile, R₁₀ and R₁₁, and the aldehyde or ketone function when present, being such that a compound of formula (III) is formed: R₁-NR₂'A'-NR₃'-B'-R₄ (III) in which R₂', A', R₃' and B' are R₂, A, R₃ and B respectively or groups convertible thereto, and thereafter, optionally or as necessary, converting R₂', A', R₃', and/or B' to R₂, A, R₃ and/or B, interconverting R₂ and/or R₃ and/or forming a pharmaceutically acceptable salt. Suitable examples of R₂' convertible to R₂ include hydrogen and C₁₋₃ alkanoyl. R₂' C₁₋₃ alkanoyl may be converted to R₂ C₁₋₃ alkyl by reduction under conventional conditions, for example with LiAlH₄ as the reducing agent in an inert solvent such as tetrahydrofuran. R₂' hydrogen may be converted to R₂ by conventional amine alkylation or acylation. In a preferred embodiment the process comprises reacting a compound of formula (IIIa): R₁-NH-A-NR₃'-B-R₄ (IIIa) wherein the variables are as defined in formula (III), (a) with a compound of formula (IV): L-R₂' (IV) wherein R₂' is R₂ as defined in formula (I) or a group convertible thereto, and L is a leaving group; (b) with a compound of formula (V): X¹=C=N-R₇ (V) wherein X¹ is O or S and R₇ is as defined in formula (I); or (c) with a compound of formula (VI): wherein R₁₂ and R₁₃ are such that is R₂ as defined in formula (I) and thereafter, optionally or as necessary, converting R₃' when a protecting group to R₃ and/or converting R₃ when hydrogen to another R₃ and/or converting R₂' to R₂ and/or converting R₂ to other R₂ and/or forming a pharmaceutically acceptable salt. In the compound of formula (IV), the leaving group L is a group readily displaceable by a nucleophile. Suitable examples of L are hydroxy, halogen such as chloro, bromo and iodo and acyloxy such as mesyloxy, tosyloxy, triflate, C₁₋₄ alkanoyloxy, C₁₋₄ alkoxycarbonyloxy and activated hydrocarbyloxy such as pentachlorophenoxy. If the leaving group is hydroxy, then the reaction is preferably carried out in an inert non-hydroxylic solvent, such as benzene, toluene or diethyl ether in the presence of a dehydrating catalyst, such as a carbodiimide, for example dicyclohexylcarbodiimide. The reaction may be carried out at a non-extreme temperature such as -10 to 100 o C, for example 0 to 80 o C. If the leaving group is a halide, then the reaction is preferably carried out at a non-extreme temperature in an inert non-hydroxylic solvent, such as trichloromethane, xylene, benzene, toluene or diethyl ether. It is also preferably carried out in the presence of an acid acceptor, such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or picoline, some of which can also function as a solvent.Alternatively, the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate. If the leaving group is acyloxy, then the reaction is preferably carried in substantially the same manner as if the leaving group were hydroxy. Suitable examples of acyloxy leaving groups include C₁₋₄ alkanoyloxy, mesyloxy, tosyloxy and triflate. If the leaving group is C₁₋₄ alkoxycarbonyloxy, then the reaction is preferably carried out in an inert solvent, such as methylenechloride, at a non-extreme temperature in the presence of an acid acceptor, such as triethylamine. If the leaving group is activated hydrocarbonyloxy then the reaction is preferably carried out in an inert polar solvent, such as dimethylformamide. It is also preferred that the activated hydrocarbyloxy group is a pentachlorophenyl ester and that the reaction is carried out at ambient temperature. When R₂ is an alkyl-type moiety, the leaving group is preferably halide or tosyloxy. When R₂ is an acyl-type moiety, the leaving group is preferably halide or hydroxy, more preferably halide. The reaction between the compounds or formulae (IIIa) and (V) may be carried out under conditions suitable for the preparation of a urea, for example in an inert solvent such as chloroform at moderate temperature, suitably the boiling point of the solvent, for example 40 o - 80 o C. The reaction between the compounds or formulae (IIIa) and (VI) may be carried out under conditions suitable for a reductive alkylation, in the presence of a suitable reducing agent such as NaCNBH₃ in an inert solvent such as methanol. Examples of N-protecting groups for R₃' include C₁₋₆ alkanoyl, for example acetyl, propionyl, n- and iso -butyryl and 2,2-dimethylpropanoyl, benzoyl or benzyl optionally substituted in the phenyl ring by one or two substituents selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, halogen or nitro; and C₁₋₄ alkoxycarbonyl, for example tert -butoxycarbonyl. Conversion of protected amino to amino may be effected conventionally. When the protecting group is C₁₋₆ alkanoyl or optionally substituted benzoyl as defined, conversion to amino is conveniently effected by conventional base hydrolysis. When the protecting group is C₁₋₄ alkoxycarbonyl or optionally substituted benzyl as defined, conversion to amino may be carried out conventionally, for example by hydrogenolysis. Suitable reactions are conventionally transition-metal catalysed hydrogenation, using for example palladium- or platinum-charcoal, at atmospheric pressure or a light excess thereover. A dry, inert, polar solvent such as dry ethanol and ambient temperatures are apt. Subsequent conversion of R₃ when hydrogen to other R₃ may be carried out by conventional amine alkylation, for example with the appropriate aldehyde or ketone in a solvent such as acetonitrile or methanol, in the presence of a reducing agent such as an alkaline porohydride e.g. sodium cyanoborohydride. Alternatively, conversion of an R₃' C₁₋₄ alkanoyl protecting group to the corresponding R₃ C₁₋₄ alkyl group may be carried out directly by reduction under conventional conditions, for example with LiAlH₄ as the reducing agent in an inert solvent such as tetrahydrofuran. Examples of group A' and B' convertible to A and B include alkylene chains containing a carbonyl group which may be reduced under conventional conditions with a suitable reducing agent such as LiAlH₄ in an inert solvent such as tetrahydrofuran. Interconversion of groups R₂ may be carried out conventionally. Thus, for example, a group R₂ of the formula COR₇ may be reduced to the corresponding alkyl group CH₂R₇ under the conditions just described for the reduction of R₃' to R₃. It will be appreciated that the selective removal or reduction of an R₃' protecting group will generally only be carried out in the presence of alkyl-type R₂ groups. Wnere R₂' and R₃' are both alxanoyl groups, similtaneous reduction of both moieties may be performed to give the corresponding R₂ and R₃ alkyl groups. In the reaction between the compounds R₁₀X and R₁₁Y, the leaving group may be any suitable group as defined above for L, such as halo, particulary chloro or bromo, tosyloxy or mesyloxy and the nucleophilic substitution reaction carried out as described above for the reaction of compounds of formulae (IIIa) and (IV), preferably in an inert solvent such as xylene, toluene or trichloromethane at elevated temperature in the presence of a base such as triethylamine. Suitable pairs of R₁₀X and R₁₁Y include: wherein L' is a leaving group and the remaining variables are as previously defined. The leaving group L' is a group readily displaceable by a nucleophile. Suitable examples for L' are as described above for L. Where X or Y is an aldehyde or ketone function, the reaction is a reductive alkylation which may be carried out conventionally, for example in a solvent such as toluene or methanol with a reducing agent such as NaBH₄ or NaCNBH₃. Suitable pairs of R₁₀X and R₁₁Y include: in which A',B', ₁, R₂', R₃' and R₄ are as previously defined, a) provides a compound of formula (I) in which the alkylene motiety -A- is of the form b) provides a moiety -B- of the form and c) provides a moiety -A- of the form Pharmaceutically acceptable salts including N-oxides of the compounds of formula (I) may be formed conventionally. The salts may be formed for example by reaction of the base compound of formula (I) with a pharmaceutically acceptable organic or inorganic acid. N-oxides are produced by reaction of a compound of formula (I) with an organic peracid, such as m-chloroperbenzoic acid in, for example, a chlorinated hydrocarbon solvent at below ambient temperature. Quaternary ammonium salts may be prepared by reaction of a compound of formula (I) with the appropriate alkyl, aryl or aralkyl, chloride, bromide or iodide. This reaction may be carried out in a solvent, such as acetone, methanol, ethanol or dimethylformamide, at ambient or elevated temperature with or without pressure. Racemates of compounds of the formula (I) may be resolved conventionally, e.g., by salification with a chiral acid if appropriate and separation of the resultant salts. Alternatively, either may be synthesised from corresponding chiral preceeding intermediates. The invention also provides novel intermediates or the formula (IIIa). Compounds of formula (IIIa) may be prepared by any suitable conventional procedures, in particular nucleophilic substitution and/or reductive alkylation by analogy with the reaction of compounds R₁₀X and R₁₁Y described above. Thus, for example, compounds of formula (IIIa) may be prepared by reacting the compound of formula (VII): R₁-NH-CO-A¹-L₁ (VII) in which L₁ is a leaving group, A¹ is a group such that CH₂A¹ represents A, and R₁ is as above defined, with a compound of formula (VIII) R₄-B-NHR₃'' (VIII) in which R₃'' is R₃' or a group convertible thereto, and R₄ and B are as above defined, to give a compound of formula (IX): R₁-NH-CO-A¹-NR₃''-B-R₄ (IX) and thereafter reducing the compound of formula (IX) and, optionally or as necessary, converting R₃'' to R₃'. The leaving group L₁ is a group readily displaceable by a nucleophile. Suitable and preferred values for L₁ are described for L as hereinbefore defined. The reaction is carried out in an analogous manner to that between compounds of formulae (IIIa) and (IV), suitably in trichloromethane in the presence of triethylamine as the acid acceptor. Where R₃' in the compound of formula (III) is an alkanoyl function, suitable groups R₃'' convertible thereto include hydrogen, which may be converted to alkanoyl by reaction with the appropriate acid halide under conditions mentioned above for the reaction of the compounds of formulae (IIIa) and (IV) where L is halide, suitably in trichloromethane in the presence of triethylamine. Alternatively, when R₃ in formula (I) is an alkyl moiety, R₃'' may be the same alkyl moiety. The reduction of the compound of formula (IX) may be carried out under conventional amide reduction conditions as described above for the reduction of R₃' to R₃, suitably with LiAlH₄ in tetrahydrofuran. Compounds of the formula (IIIa) in which the alkylene moiety -A- is of the form may be prepared by the reductive alkylation of compound of formula (X): R₁NH₂ (X) in which R₁ is as above defined, with a compound of formula (XI): where the variables are as above defined, followed by the optional conversion of R₃'' to R₃' as described above. The reductive alkylation may be carried out conventionally for example in a solvent such as toluene with a reducing agent such as NaBH₄. Compounds of formula (IIIa) may alternatively be prepared by reacting a compound of formula (XII): R₁-NH-A-NH₂ (XII) wherein the variables are as above defined, with a compound of formula (XIII): R₄BL₃ (XIII) wherein L₃ is a leaving group and the remaining variables are as above defined, as described above for the nucleophilic substitution reaction of compounds R₁₀X and R₁₁Y. Examples of the leaving group L₃ include those described below for L₂. Compounds R₁₀X and R₁₁Y are known compounds or may be prepared by processes analogous to those for preparing known compounds. Thus, for example, compound R₁₁Y such as compounds of formula (XI) may be prepared by the reaction of a compound of formula (XIV): in which L₂ is a leaving group and A² and A³ are as above defined, with a compound of formula (VIII) above, followed by deprotection of the protected carbonyl moiety under acid conditions. The reaction between the compounds of formulae (XIV) and (VIII) is preferably carried out in an inert solvent such as CHCl₃, with heating in the presence of a base such as triethylamine. Examples of the leaving group L₂ include halogen, tosylate, or other leaving groups described above for L. Compounds R₁₁Y of the form. may be prepared as follows: where L₄ is a leaving group such as described above for L₃ and the remaining variables are as previously described, under mildly basic conditions such as K₂CO₃ in an inert solvent such as dimethylformamide. Suitable examples of the groups L' and L₄ are chloro and bromo respectively. Compounds R₁₀X of the form: may be prepared as follows: where L₅ is a leaving group such as described for L₄ and the remaining variables are as previously descibed, in an inert solvent such as described above for the reaction or R₁₀X and R₁₁Y. Compounds R₁₀X of the form: may be prepared as follows: where L₆ is a leaving group such as described above for L₂ and the remaining variables are as defined, in an inert solvent such as described above for the reaction for the reaction of R₁₀X and R₁₁Y, in the presence of a base such as triethylamine at elevated temperature, followed by deprotection with acid. Compounds R₁₀X of the form: such as compounds of formula (XII) may be prepared by the reaction of a compound of formula (XV) wherein each of A⁶, A⁷ and A⁸ is hydrogen or alkyl such that is A as above defined, with a compound of formula (XVI): followed by reduction of the resulting nitrile. The reaction of the compounds of formulae (XV) and (XVI) is base catalysed, and the reduction step may be carried out using LiAlH₄. The compounds of formulae (IV) to (VIII), (X) and (XIII) to (XVI), and analogous compounds R₁₀X and R₁₁Y are known compounds or may be prepared by processes analogous to those for preparing known compounds. Thus, compounds of formula (VII) may be prepared by reaction of the appropriately substituted aniline with a compound L₁A¹COCl under the conditions mentioned above for the reaction of the compounds of formulae (IIIa) and (IV). Compounds of formula (VIII) may be prepared by the conventional amine alkylation or acylation of a compound R₄BNH₂ under similar conditions. The invention therefore provides a process for the preparation of a compound of formula (IB) which process comprises reacting together R₁₀X and YR₁₁ as hereinbefore defined, to give a compound of formula (III) as defined, and thereafter, optionally or as necessary, converting R₂', A', R₃' and /or B'to R₂, A, R₃ and/or B, interconverting R₂ and/or R₃ and/or forming a pharmaceutically acceptable salt. The following examples illustrate the invention and the following descriptions illustrate intermediates thereto. Description 1 a) 3-(3,4-Dimethoxyphenyl)-1-chloro-propionamide (D1a) To a stirred dry solution of 85 g 3-chloropropionylchloride in 500 ml chloroform, a solution of 75 g 3,4-dimethoxyaniline and 54 g triethylamine in 200 ml chloroform was added dropwise with cooling at about 8 - 10 o C. The solution was then kept overnight at room temperature. Thereafter, the solution was extracted with 1M NaOH and 0.5 icewater. The organic phase was neutralised, separated and dried over Na₂SO₄. The solvent was concentrated so that a white product was precipitated which was washed three times with ether. The yield of the white crystalline product D1a was 60% and TLC-pure. b) 2-(3,4-Dimethoxyphenyl)-1-chloro-acetamide (D1b) Compound D1b was prepared by the procedure of a) above, but using 2-chloroacetylchloride as the acylating agent. Description 2 a) 1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino] -3-propion-(3,4-dimethoxy)-anilide.(D2a) (i) N-Methoxycarbonyl-2-(3,4-dimethoxyphenyl)-ethylamine Equimolar amounts of 2-(3,4-dimethoxyphenyl)-ethylamine, triethylamine and methyl chloroformate in dry tetrahydrofuran were mixed together carefully at around 20 o C. After reaction overnight at room temperature, the solid was sucked off, the solvent evaporated and the residue extracted with small amounts of water in dichloromethane. After drying, the solvent was removed. The thus obtained product N-methoxycarbonyl-2-(3,4-dimethoxphenyl)-ethylamine in nearly quantitative yield is sufficiently pure for further reaction. (ii) N-Methyl-2-(3,4-dimethoxyphenyl)-ethylamine The product of (i) was reduced in dry tetrahydrofuran or diethylether in conventional manner by the addition of 3 equivalents of LiAlH₄ and subsequent refluxing of the mixture for 0.5-1hr. After cooling and filtration, the solvent was evaporated and the product obtained by first extraction of the ethereal phase at pH 4, then at pH 10 with methylene chloride. Drying and evaporation of the solvent yielded 50-60% nearly pure oily product. (iii)1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino] -3-propion-(3,4-dimethoxy)-anilide (title compound) To a solution of 51g 3-(3,4-Dimethoxyphenyl)-1-chloropropionamide (D1a) in 900 ml acetonitrile, 40 g N-methyl-2-(3,4-dimethoxyphenyl)-ethylamine from (ii) and 24 g triethylamine were added and the mixture refluxed for 7h under moisture protection. The solvent was removed in vacuo and the residue was extracted several times with ether at pH 6-7. Then the inorganic phase at PH 10 was extracted with methylenechloride, washed with water, dried over Na₂SO₄ and the organic solvent removed in vacuo . Yield; 70 g yellow oil = 65%. The compound was sufficiently pure for further reaction. b) 1-[N-methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino]-2-acet-(3,4-dimethoxy)anilide. (D2b) Compound D2b was prepared by the procedure of a) above but using intermediate D1b. Description 3 1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino]-propyl-3-(3,4-dimethoxy)-aniline (D3) To a suspension of 6 g LiAlH₄ in 270 ml absolute tetrahydrofuran, a solution or 42 D2a in 240 ml THF was added dropwise under stirring, while the solvent was gently boiling. The mixture was refluxed for 2h, then stirred at room temperature for 1h. Then excess LiAlH₄ and the complex formed was hydrolysed in the usual way by dropwise successive addition of 4.5 ml H₂O, 4.5 ml 15% NaOH and 14 ml water. After stirring for 1 h, the white precipitate was sucked off, washed carefully with THF and the filtrate evaporated to dryness in vacuo . The resulting dark green oil was extracted at pH 7 - 7.5 with excess ether. Then the aqueous phase at pH 12-13 was extracted with ether several times, and the extract washed with a small amount of water, dried over Na₂SO₄ and evaporated to dryness in vacuo . 32 g = 80% of a dark green oil was obtained, sufficiently pure for further reaction. The oil formed a crystalline grey-white hydrochloride when treated with ethanolic hydrochloride in refluxing absolute tetrahydrofuran. M.pt. 153 o C. Description 4 1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino]-ethyl-2-(3,4-dimethoxy)-aniline (D4) Compound D4 was prepared by the procedure of Description 3 but using intermediate D2b. The following compounds of Descriptions 5 to 8 were prepared analogously to compound D3. Description 5 1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)ethylamino]-propyl-3-aniline (D5) Description 6 1-[N-Methyl-N-2-phenylethylamino]propyl-3-(3,4-dimethoxy)-aniline (D6) Description 7 1-[N-Methyl-N-2-phenylethylamino]propyl-3-aniline (D7) Description 8 1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)ethylamino]-propyl-3-(4-chloro)-aniline (D8) Example 1 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-nitro)-benzylamine (E1) 10 g 1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino]-propyl)-3-(3,4-dimethoxy)-aniline (D3), 3 g triethylamine and 5 g 2-nitrobenzyl-chloride in 100 ml chloroform were refluxed under protection from moisture for 8h. To complete the reaction, 0.7 g 2-nitrobenzylchloride and 0.5 g triethylamine were added and refluxed for another 2h. Then the solvent was removed in vacuo and the residue extracted with ether several times at pH 6 and then extracted with dichloromethane twice at pH9. After drying over Na₂SO₄, the CH₂Cl₂-phase was concentrated and the product purified by column-chromatography on Al₂O₃, using methylene chloride with 1-2% methanol as eluent. Yield was 4 g of nearly pure material (red oil) ≅ 31%. In another bath, the raw material was purified using preparative TLC on silicagel with chloroform/methanol (9/1) as eluent. Yield was 22% of pure, red oily product. Nmr (CDCl₃): 1.55-2.0(m,2H): 2.29(s,3H); 2.35-2.8(m,6H); 3.39(t(J=7.3Hz),2H); 3.75(s,3H); 3.78(s,3H), 3.82(s,3H); 3.85(s,3H); 4.83(s,2H); 6.05-6.35 (m,2H); 6.6-6.85(m,4H); 7.3-7.6(m,3H); 8.0-8.2(m,1H) Example 2 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-cyanamide (E2) Compound E2 was prepared by reaction of 1 g amine D3 in 10 ml chloroform and 1 g K₂CO₃ with 0.32 g bromocyan (BrCN) at 0 o C. Reaction was completed by stirring the mixture at room temperature for 1 h. After removing the solid by filtration and evaporation of the solvent in vacuo , the residue was purified by TLC-chromatography as described in Example 1. Yield: 0.3 g ≅ 30% of an red oily product. Elementary Analysis: C H N calc. 66.80 7.55 10.16 found 66.74 7.49 10.14 Example 3 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-cyanomethylamine (E3) Compound E3 was prepared from intermediate D3 and cyanomethylbromide by the procedure of Example 1. Elementary Analysis: C H N calc. 67.42 7.78 9.83 found 67.35 7.66 9.78 The compounds of the following Examples 4 to 7 were prepared from intermediate D3 and the appropriately substituted benzylchloride by the procedure of Example 1: Example 4 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-benzylamine (E4) Elementary Analysis: C H N calc. 72.77 8.00 5.85 found 72.69 8.04 5.78 Nmr (CDCl₃): 1.55-2.0(m,2H); 2.27(s,3H); 2.3-2.8(m,6H); 3.36(t(J=7.3Hz),2H); 3.74(s,3H); 3.78(s,3H); 3.84(s,6H); 4.44(s,2H); 6.1-6.45(m,2H), 6.6-6.9(m,4H); 7.1-7.4(m,5H). Example 5 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(3-nitro)-benzylamine (E5) Nmr (CDCl₃): 1.55-2.05(m,2H); 2.28(s,3H); 2.3-2.8(m,6H); 3.38(t(J=7.4Hz),2H); 3.77(s,3H); 3.79(s,3H); 3.83-3.84(2xs, 6H); 4.49(s,2H); 6.1-6.4(m,2H); 6.6-6.9(m,4H); 7.3-7.7(m,2H); 7.95-8.2(m,2H). Example 6 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-nitro)-benzylamine (E6) Nmr (CDCl₃): 1.55-2.0(m,2H); 2.28(s,3H); 2.3-2.8(m,6H), 3.37(t(J=7.5Hz),2H), 3.76(s,3H); 3.78(s,3H), 3.83(s,3H), 3.84(s,3H), 4.5(s,2H), 6.1-6.4(m,2H), 6.55-6.9(m,4H); 7.38(d(J=8.7Hz),2H); 8.1(d(J=8.7Hz),2H). Example 7 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-methyl)-benzylamine (E7) Nmr (CDCl₃): 1.5-2.0(m,2H); 2.28(s,3H); 2.31(s,3H); 2.35-2.8 (m,6H); 3.35(t(J=7.5Hz),2H); 3.76(s,3H); 3.78(s,3H); 3.84(s,6H); 4.41(s,2H); 6.15-6.45 (m,2H), 6.55-6.85(m,4H); 6.9-7.2(m,4H). The compounds of the following Examples 8 and 9 were prepared from intermediate D4 and the appropriately substituted benzylchloride by the procedure of Example 1: Example 8 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-benzylamine (E8) Nmr (CDCl₃): 2.34(s,3H); 2.5-2.8(m,6H); 3.49(t(J=7.7Hz),2H), 3.74(s,3H); 3.79(s,3H); 3.84(s,6H); 4.47(s,2H); 6.1-6.45(m,2H); 6.6-6.9(m,4H); 7.1-7.4(m,5H). Example 9 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(3-nitro)-benzylamine (E9) Nmr (CDCl₃): 2.33(s,3H); 2.45-2.8(m,6H); 3.48(t(J=7.2Hz),2H); 3.76(s,3H); 3.79(s,3H); 3.84(s,6H); 4.51(s,2H); 6.1-6.4(m,2H), 6.55-6.9(m,4H); 7.3-7.7(m,2H); 8.0-8.2(m,2H). The structure of the compounds of Examples 3 to 9 are illustrated in the following Table 1: Example 10 (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-butanoic acid amide (E10) 1 g Amine D3, 0.3 g triethylamine and 0.32 g butyric acidchloride in 40 ml dry chloroform was refluxed for 3h. Isolation of the pure red oily product was achieved according to the procedure described in Example 1. Yield 0.74 g ≅ 65% Nmr (CDCl₃): 0.83(t(J=6.8Hz),3H); 1.35-2.2(m,6H); 2.25(s,3H), 2.3-2.8(m,6H); 3.6-4.0(m+2s,14H); 6.6-7.0(m,6H). The compounds of the following Examples 11 to 19 were prepared from intermediate D3 and the appropriate acid chloride by the procedure of Example 10: Example 11 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-methyl)-propanoic acid amide (E11) Elementary Analysis: C H N calc. 68.10 8.35 6.11 found 68.12 8.42 5.91 Nmr (CDCl₃): 1.02(d(J=6.7Hz),6H); 1.5-1.95(m,2H); 2.26(s,3H), 2.3-2.8(m,7H), 3.5-4.0(m+2s,14H); 6.55-7.0 (m,6H). Example 12 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-pentanoic acid amide (E12) Nmr (CDCl₃): 0.82(t(J=6.2Hz),3H); 1.0-2.2(m,8H); 2.25(s,3H), 2.3-2.8(m,6H); 3.55-4.0(m+s,14H); 6.6-7.0(m,6H). Example 13 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-benzamide (E13) Elementary Analysis: C H N calc. 70.71 7.36 5.68 found 70.60 7.38 5.64 Example 14 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-phenyl)-ethanoic acid amide (E14) Elementary Analysis: C H N calc. 71.12 7.56 5.53 found 71.19 7.55 5.47 Example 15 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(3-phenyl)-propanoic acid amide (E15) Nmr (CDCl₃): 1.4-1.95(m,2H); 2.24(s,3H); 2.3-3.05(m,10H); 3.5-3.95(m+2s,14H): 6.4-6.9(m,6H); 7.0-7.4(m,5H). Example 16 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-methyl)-phenyl sulphonamide (E16) Elementary Analysis C H N calc. 64.18 7.05 5.16 found 64.09 7.02 5.15 Example 17 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-dodecanoic acid amide (E17) Nmr (CDCl₃): 0.87(t(J=5.2Hz),3H), 1.0-2.2(m,22H); 2.26(s,3H); 2.3-2.8(m,6H); 3.6-4.0(m+2s,14H); 6.6-7.0(m,6H). Example 18 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-octanoic acid amide (E18) Nmr (CDCl₃): 0.84(t(J=7Hz),3H); 1.0-2.2(m,14H); 2.25(s,3H), 2.3-2.8(m,6H); 3.5-4.0(m+2s,14H); 6.55-7.0(m,6H). Example 19 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-hexanoic acid amide (E19) Nmr (CDCl₃): 0.84(t(J=5.3Hz),3H), 1.0-2.2(m,10H), 2.27(s,3H), 2.3-2.8(m,6H); 3.5-4.0(m+2s,14H); 6.6-7.0(m,6H). The compounds of the following Examples 20 to 23 were prepared from intermediate D4 and the appropriate acid chloride by the procedure of Example 10: Example 20 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-dodecanoic acid amide (E20) Nmr (CDCl₃): 0.87(t(J=6Hz),3H); 1.0-1.8(m,18H); 1.8-2.15(m,2H), 2.3(s,3H); 2.35-2.8(m,6H); 3.355-3.95 (m+3s,14H); 6.55-6.95(m,6H). Example 21 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-pentanoic acid amide (E21) Nmr (CDCl₃): 0.82(t(J=6.2Hz),3H); 0.95-1.8(m,4H); 1.9-2.2 (m,2H); 2.30(s,3H); 2.4-2.8(m,6H); 3.6-3.95 (m+3s,14H); 6.5-6.95(m,6H). Example 22 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(2-methyl)-propanoic acid amide (E22) Nmr (CDCl₃): 1.02(d(J=6.7Hz),6H); 2.30(s,3H); 2.35-2.8(m,7H), 3.6-3.95(m+s, 14H), 6.65-6.95(m,6H). Example 23 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(3-phenyl)-propanoic acid amide (E23) Nmr (CDCl₃): 2.29(s,3H); 2.A-3.05(m,10H); 3.6-3.95(m+3s,14H); 6.4-6.9(m,6H); 7.0-7.35(m,5H). The structures of the compounds of Example 11 to 23 are illustrated in Table 1: Example 24 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3, 4-dimethoxyphenyl)-ethyl-N'methylamino]-propyl)-n-butyl-urethane (E24) 1 g Amine D3, 0.3 g triethylamine and 0.37 g n-butylchloro-formate in 20 ml chloroform were refluxed for 4h. Isolation of the pure red oily product was achieved according to the procedure described in Example 1. Yield: 0.9 g ≅ 74% Elementary Analysis: C H N calc. 66.37 8.25 5.73 found 66.47 8.25 5.76 Example 25 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-phenyl-urethane (E25) Compound E25 was prepared from intermediate D3 and phenyl chloroformate by the procedure of Example 24. Elementary Analysis: C H N calc. 68.48 7.13 5.50 found 68.58 7.22 5.39 Example 26 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-n-butyl-urea (E26) 1 g Amine D3 and 0.28 g n-butylisocyanate in 25 ml chloroform were refluxed for 2h. After removing the solvent in vacuo , the pure product was isolated by TLC-chromatography as described in Example 1.. Yield : 0.9 g ≅ 75% of an red, oily product Nmr (CDCl₃): 0.87(t(J=6.0Hz),3H); 1.1-1.55(m,4H), 1.55-1.95(m,2H); 2.26(s,3H); 2.3-2.8(m,6H), 3.0-3.35(m,2H); 3.5-3.95(m+2s(3.85, 3.89),14H); 4.3A(t exch.D₂O,1H); 6.55-7.0(m,6H). The compounds of the following Examples 27 to 31 were prepared from intermediate D3 and the appropriate isocyanate by the procedure of Example 26: Example 27 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-n-propyl-urea (E27) Elementary Analysis: C H N calc. 65.93 8.30 8.87 found 65.87 8.29 8.51 Example 28 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-i-propyl-urea (E28) Elementary Analysis: C H N calc. 65.93 8.30 8.87 found 65.98 8.23 8.82 Example 29 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-t-butyl-urea (E29) Elementary Analysis: C H N calc. 66.50 8.47 8.61 found 66.38 8.46 8.71 Example 30 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-benzylurea (E30) Nmr (CDCl₃): 1.5-1.95(m,2H); 2.25(s,3H); 2.3-2.85(m,6H); 3.6-3.95(m+3s,14H); 4.41(d(J=5.8Hz),exch.D₂O s,2H); 4.82(t(J=5.8Hz)exch.D₂O,1H); 6.6-6.95 (m,6H); 7.1-7.45(m,5H). Example 31 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-phenylurea (E31) Elementary Analysis: C H N calc. 68.61 7.34 8.27 found 68.28 7.28 7.94 The compounds of the following Examples 32 and 33 were prepared from intermediate D4 and the appropriate isocyanate by the procedure of Example 26: Example 32 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl-N''-(1-phenyl)-ethyl-urea (E32) Nmr (CDCl₃): 1.35(d(J=6.7Hz),3H); 2.29(s,3H); 2.4-2.75 (m,6H); 3.6-3.95(m+3s,14H); 4.76(t(J=8Hz), 1H exch.D₂O); 4.96(q(J=6.8Hz),1H), 6.65-6.9(m,6H); 7.1-7.4(m,5H). Example 33 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl-N''-n-propyl-urea (E33) Nmr (CDCl₃): 0.82(t(J=6.8Hz),3H); 1.1-1.6(m,2H), 2.32(s,3H), 2.45-2.8(m,6H); 2.9-3.3(m,exch.D₂O to 3.15, t(J=5.84),2H); 3.65-3.95(m+2s,14H), 4.36(t(J=5Hz) exch.D₂O,1H); 6.55-6.95 (m,6H). The structures of the compounds of Examples 25 and 27 to 33 are illustrated in Table 1: Example 34 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-n-pentylamine (E34) A mixture of 1.7 g E12 and 0.13 g LiAlH₄ in 16 ml dry tetrahydrofuran was refluxed under protection from moisture for 2h. Thereafter, the product was worked up according to the procedure described for compound D3. Pure product was obtained by TLC as described for Example 1. Yield: 0.24 g = 15% of a oily red product Nmr (CDCl₃): 0.9(t(J=5.2Hz),3H); 1.1-2.0(m,8H); 2.30(s,3H), 2.34-2.8(m,6H); 3.0-3.4(m,4H); 3.8(s,3H); 3.84(s,9H), 6.1-6.45(m,2H), 6.6-6.95(m,4H). Hydrochloride salt m.pt. 191 o C (prepared by treatment of the free base in ethyl acetate with ethanolic HCl. The salt crystallised on cooling and was washed with ether). Example 35 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]ethyl)-n-pentylamine (E35). The title compound was prepared from compound E21 by the procedure of Example 34. Nmr (CDCl₃): 0.91(t(J=6Hz),3H), 1.1-1.8(m,6H): 2.38(s,3H); 2.4-2.85(m,6H), 3.05-3.5(m,4H), 3.81, 3.85, 3.86(s,s,s,12H); 6.1-6.4(m,2H); 6.55-6.9(m,4H). The compounds of Examples 34 and 35 have also been prepared from compounds D3 and D4 respectively by the procedure of Example 1 but using n-pentyliodide in place of 2-nitrobenzyl chloride. Yield 20-35%. The compound of Example 34 has also been prepared from compound D3 and valeraldehyde by the procedure of Example 61 at pH3. Yield 50-60%. The compounds of the following Examples 36 to 46 were prepared from intermediate D3 (Examples 36 to 44) or D2 (Examples 45 and 46) by the procedure of Example 1. Example 37 utilized 3-(3-methoxyphenyl)-1-bromopropane. Example 44 utilized 2-chloro-3,5-dinitropyridine. The remaining examples utilized the appropriate alkyl chloride. Example 36 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-3,5-dinitrobenzylamine Nmr (CDCl₃): 1.55-2.0(m,2H); 2.29(s,3H); 2.3-2.9(m,6H), 3.2-3.55(m,2H), 3.78, 3.80, 3.83(3s,12H); 4.53(s,2H); 6.1-6.5(m,2H); 6.6-6.9(m,4H); 8.35-8.5 (m,2H); 8.8-8.95(m,1H). Example 37 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-3-(3-methoxy-phenyl)-propylamine Nmr (CDCl₃): 1.5-2.1(m,4H); 2.29(s,3H); 2.3-3.0(m,8H); 3.1-3.4(m,4H); 3.77, 3.79, 3.84, 3.85(4s,15H), 6.1-6.4(m,2H); 6.6-6.95(m,7H); 7.0-7.3(m,1H). Example 38 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-2,5-dimethyl-benzylamine Nmr (CDCl₃): 1.5-2.0(m,2H); 2.25, 2.28 (2s,9H); 2.3-2.9(m,6H); 3.2-3.55(m,2H), 3.76, 3.79,3.84, 3.85(4s,12H); 4.34(s,2H); 6.1-6.4(m,2H); 6.6-7.2(m,7H) Example 39 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-trifluoromethyl-benzylamine Nmr (CDCl₃): 1.5-2.1(m,2H), 2.29(s,3H); 2.3-2.8(m,6H), 3.25-3.6(m,2H), 3.7, 3.77, 3.82, 3.84(4s,12H); 4.67(s,2H); 6.05-6.3(m,2H); 6.6-6.9(m,4H), 7.25-7.5(m,3H); 7.5-7.75(m,1H). Example 40 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3-trifluoromethyl-benzylamine Nmr (CDCl₃): 1.5-2.0(m,2H); 2.27(s,3H); 2.3-2.9(m,6H); 3.2-3.5(m,2H); 3.75, 3.79, 3.83, 3.84(4s,12H), 4.46(s,2H), 6.1-6.4(m,2H); 6.55-6.9(m,4H); 7.3-7.65(m,4H). Example 41 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2,4,6-trimethyl-benzylamine Nmr (CDCl₃): 1.4-1.85(m,2H); 2.1-2.4(m + 2s (2.19, 2.27), 14H); 2.4-3.2(m,6H); 3.76, 3.82, 3.84(3s, 12H);4.17(s,2H); 6.35-6.9(m,8H). Example 42 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2,6 dichlorobenzyl-amine Nmr (CDCl₃): 1.4-1.9(m,2H), 2.21(s,3H), 2.25-2.28(m,6H), 3.0-3.3(m,2H), 3.81,3.84(2s,12H); 4.5(s,2H), 6.4-6.9(m,6H); 6.95-7.4(m,3H). Example 43 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-chloro-3,4-methylenedioxobenzylamine Nmr (CDCl₃): 1.55-2.0(m,2H); 2.3(s,3H); 2.35-2.9(m,6H), 3.2-3.55(m,2H); 3.77, 3.78, 3.83, 3.85(4s,12H); 4.41(s,2H); 5.90(s,2H), 6.05-6.35(m,2H); 6.6-6.9(m,6H). Example 44 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3,5-dinitro-2-amino-pyridine Nmr (CDCl₃): 1.5-2.1(m,2H); 2.26(s,3H); 2.3-2.8(m,6H), 3.82, 3.84, 3.86(3s,12H); 4.0-4.3(m,2H), 6.5-6.9(m,6H); 8.61(d(J=2.5Hz),1H), 9.17(d(J=2.5Hz),1H). Example 45 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-ethyl)-4-nitro-benzyl-amine Nmr (CDCl₃): 2.33(s,3H), 2.5-2.8(m,6H); 3.3-3.6(m,2H), 3.75, 3.79, 3.84(3s,12H); 4.52(s,2H); 6.05-6.4(m,2H), 6.55-6.9(m,4H), 7.3-7.5(m,2H), 8.05-8.25(m,2H). Example 46 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl) benzylamine Nmr (CDCl₃): 2.34(s,3H), 2.5-2.9(m,6H); 3.35-3.65(m,2H); 3.74, 3.79, 3.84(3s,12H); 4.47(s,2H); 6.1-6.45(m,2H); 6.6-6.95(m,4H); 7.1-7.4(m,5H). Example 47 (N-[3,4-Dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-ethyl) phenylacetamide Nmr (CDCl₃): 2.29(s,3H); 2.4-2.75(m,6H); 3.44(s,2H); 3.55-4.0(m + 3s (3.69, 3.84, 3.90),14H), 6.5-7.5(m,11H). The compounds of the following Examples 47 to 56 were prepared from amine D2 (Example 47) or D3(Example 48 to 56) and the appropriate acid chloride by the procedure of Example 10. Example 56 utilized the acid chloride 3-phenyl-2-acetoxy-propanoic acid chloride prepared from L(-) phenyl lactic acid by conversion to the acetate by reaction with acetyl chloride in chloroform in the presence of triethylamine, followed by conversion to the acid chloride by treatment with thionyl chloride in chloroform. Example 48 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl]-4-(4'-nitrophenyl)-butyramide Nmr (CDCl₃): 1.5-2.2(m,6H); 2.25(s,3H); 2.3-3.0(m,8H), 3.55-3.8(m,2H), 3.84,3.85, 3.89(3s,12H); 6.5-6.95(m,6H), 7.25(d(J=8.8Hz),2H), 8.09(d(J=8.8Hz),2H). Example 49 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-nitrophenyl)-acetamide Nmr (CDCl₃): 1.5-1.95(m,2H); 2.25(s,3H); 2.3-2.95(m,6H); 3.53(s,2H), 3.6-3.75(m,2H); 3.79, 3.85, 3.92(3s,12H); 6.45-7.0(m,6H), 7.25(d(J=8.7Hz),2H); 8.09(d(J=8.7Hz),2H). Example 50 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-N'-4-nitrobenzamide Nmr (CDCl₃): 1.6-2.05(m,2H); 2.27(s,3H); 2.3-2.9(m,6H); 3.6-4.1(m+4s(3.73,3.81,3.85,3.86),14H); 6.4-6.9(m,6H); 7.44(d(J=8.9Hz),2H); 8.03(d(J=8.9Hz),2H). As the hydrochloride salt: m.pt. 84 o C elementary analysis: C H N O Cl calc. 60.67 6.32 7.32 19.51 6.18 found: 60.27 6.30 7.30 19.85 5.93 Example 51 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-metpyl-amino]-propyl)-n-heptanamide Nmr (CDCl₃): 0.7-1.0(A(m),3H); 1.0-2.2(m,12H); 2.27(s,3H); 2.3-2.9(m,6H); 3.5-3.8(m,2H); 3.84, 3.86, 3.90(3s,12H); 6.6-7.0(m,6H). Example 52 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-4-cyanobenzamide hydrochloride m.pt. 86 o C Nmr (CDCl₃): 2.1-2.6(m,2H); 2.81(d(J=4Hz), after D₂O exch.s, 3H); 2.95-3.5(m,6H); 3.8, 3.85, 3.99 (s,s,t(J=6Hz),14H); 6.4-7.0(m,6H); 7.3-7.8(m,4H); 12.7(exch.D₂O,1H). Example 53 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-4-trifluoromethylbenzamide hydrochloride m.pt. 67 o C Nmr (CDCl₃): 2.1-2.6(m,2H); 2.83(s,3H); 2.9-3.5(m,6H); 3.78, 3.81, 3.86, 4.01 (s,s,s,t(J=6.6Hz),14H); 6.4-7.0(m,6H); 7.3-7.65(m,4H); 12.5 (D₂O exch., 1H). Example 54 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl]-3,5-dinitrobenzamide hydrochloride m.pt. 128 o C Nmr (CDCl₃): 2.0-2.6(m,2H); 2.84(d(J=4.7Hz) after D₂O exch. s,3H); 2.9-3.5(m,6H); 3.8, 3.87, 4.04 (s,s,t(J=6.5Hz),14H); 6.6-7.0(m,6H); 8.53(d(J=1.7Hz),2H); 8.89(d(J=1.7Hz),1H); 12.7(exch. D₂O,1H). Example 55 (N-[3,4-Dimethoxyphenyl]-N-3-(N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-4-chlorobenzamide hydrochloride m.pt. solid foam Nmr (CDCl₃): 2.1-2.6(m,2H); 2.8(s,3H); 2.9-3.4(m,6H); 3.79, 3.82, 3.85, 3.86 (4s + t(J=6.6Hz),14H); 6.4-6.9(m,6H); 7.0-7.4(m,4H); 12.5(exch.D₂O, 1H). Example 56 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-(3-phenyl-2-acetoxy)-propanoic acid amide hyarochloride m.pt. 167 o C Nmr (CDCl₃): 2.0-2.6(m + s(2.25),5H); 2.82(d(J=4.3Hz) after D₂O exch. s,3H); 3.0-3.6(m,6H); 3.6-4.3(m + 4s(3.75, 3.81, 3.84, 3.86),17H); 6.5-7.35(m,11H); 12.5(exch. D₂O,1H). Example 57 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-N-4-nitrophenylurea The title compound was prepared from amine D3 and p-nitrophenylisocyanate by the procedure of Example 26. Nmr (CDCl₃): 1.55-2.0(m,2H); 2.32(s,3H); 2.35-2.9(m,6H); 3.6-4.0(m + 3s (3.84, 3.88, 3.92),14H); 6.5-7.0(m,6H); 7.45(d(J=9.2Hz),2H); 7.55(m,1H, exch. with D₂O); 8.11(d(J=9.2Hz),2H). The compounds of the following Examples 58 to 60 were prepared from intermediate D3 and the appropriate alkylchloroformate by the procedure of Example 24. Example 58 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-hexyl-urethane Nmr (CDCl₃): 0.86(A,3H); 1.0-2.0(m,10H), 2.25(s,3H), 2.3-2.9(m,6H); 3.66(A(J=7Hz),2H); 3.84, 3.85, 3.87 (3s,12H); 4.07(A(J=6.3Hz),2H); 6.5-6.95(m,6H). Example 59 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-octyl-urethane Nmr (CDCl₃): 0.87(m(A),3H), 1.1-2.0(m,14H); 2.25(s,3H), 2.3-2.9(m,6H); 3.5-3.8(m(A),2H), 3.84, 3.85, 3.87 (3s,12H); 3.95-4.2(m(A),2H); 6.5-6.95(m,6H). Example 60 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-5-(-)-menthyl-urethane Nmr (CDCl₃): 0.75-2.1(m,20H); 2.25(s,3H); 2.3-2.9(m,6H), 3.5-3.8(m,2H); 3.84, 3.85, 3.87 (3s,12H); 4.4-4.8(m,1H); 6.5-6.95(m,6H). Example 61 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-cyclohexyl-amine 1g Amine (D3) was dissolved in 30ml absolute methanol and ethanolic-HCl was added to pH 7. Then 0.3g cyclohexanone, 0.5g NaCNBH₃ and 3 A molecular sieve was added and the mixture stirred for three days at room temperature. For working up, the solid was filtered off, the filtrate evaporated to dryness and the residue at pH 12 extracted with methylene chloride. The extract was washed with water, dried over Na₂SO₄ and concentrated. The pure, oily product was isolated by TLC as described in Example 1. Yield: 0.09g ≅ 7% Nmr (CDCl₃): 1.0-2.1(m,12H); 2.28(s,3H), 2.3-2.9(m,7H), 2.95-3.3(m,2H); 3.81, 3.84 (2s,12H), 6.2-6.5(m,2H); 6.6-6.95(m,4H). The compounds or the following Examples 62 to 64 were prepared from amine D3 and the appropriate aldehyde or ketone by the procedure of Example 61. Example 62 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-isopropylamine. Nmr (CDCl₃): 1.12(d(J=6.6 Hz), 6H); 1.5-1.9(m,2H); 2.28(s,3H); 2.3-3.25(m,8H); 3.6-3.9(m + 3s(3.81,3.84,3.85),13H); 6.2-6.5(m,2H); 6.6-6.85(m,4H). Example 63 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-hexylamine Nmr (CDCl₃): 0.89(A,3H); 1.1-2.0(m,10H); 2.3(s,3H); 2.35-2.9(m,6H); 3.0-3.4(m,4H); 3.80, 3.84, 3.85 (3s,12H); 6.1-6.45(m,2H); 6.6-7.0(m,4H). Example 64 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxypnenyl)-ethyl-N'-methylamino]-propyl)-butylamine Nmr (CDCl₃): 0.94(A(J=6Hz),3H); 1.1-2.0(m,6H), 2.3(s,3H), 2.35-3.0(m,6H); 3.0-3.4(m,4H); 3.80(s,3H); 3.85(s,9H); 6.1-6.45(m,2H); 6.6-7.0(m,4H). Example 65 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino-propyl]-1-(3-oxo)-butyramide The title compound was prepared by the reaction of amine D3 with 1.1 equivalents of diketene in methylene chloride at room temperature for 4 hours. Nmr (CDCl₃): 1.55-2.0(m,2H); 2.10(s,3H), 2.26(s,3H); 2.3-3.0(m,6H); 3.28(s,2H); 3.55-3.95(m + 4s(3.84,3.86,3.89,3.90),14H); 6.55-7.0(m,6H). The structured of the compounds of Examples 36 to 65 are illustrated in the following Table 1: The compounds of Examples 66 to 68 were prepared from the amine D5 and the corresponding alkyl chloride by the procedure of Example 1. Example 66 (N-Phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-4-nitro-benzylamine. Nmr (CDCl₃): 1.55-2.05(m,2H); 2.29(s,3H); 2.3-2.9(m,6H); 3.46(A(J=7.2Hz),2H); 3.82(s,3H); 3.84(s,3H), 4.59(s,2H); 6.5-6.95(m,6H); 7.0-7.5(m,4H); 8.15(d(J=8.7Hz),2H). Example 67 (N-Phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3-nitro-benzylamine. Nmr (CDCl₃): 1.55-2.05(m,2H), 2.29(s,3H); 2.30-2.9(m,6H); 3.48(A(J=7.2Hz),2H); 3.82(s,3H); 3.84(s,3H); 4.59(s,2H); 6.5-6.9(m,6H); 7.05-7.6(m,4H); 7.95-8.2(m,2H). Example 68 (N-Phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-nitro-benzylamine. Nmr (CDCl₃): 1.55-2.0(m,2H); 2.30(s,3H); 2.35-2.9(m,6H); 3.45(A(J=7.2Hz),2H); 3.82(s,3H); 3.84(s,3H); 4.93(s,2H); 6.4-6.9(m,6H); 7.0-7.6(m,5H); 8.0-8.3(m,1H). Example 69 (N-Phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-valeramide Nmr (CDCl₃): 0.8(A(J=6.2Hz),3H); 0.95-2.2(m,8H); 2.24(s,3H);2.3-2.9(m,6H); 3.55-3.8(m,2H); 3.84(s,3H); 3.85(s,3H); 6.55-6.95(m,3H); 7.0-7.6(m,5H). The title compound was prepared from amine D5 and pentanoic acid chloride by the procedure of Example 10. The structures of the compounds of Examples 66 to 69 are illustrated in the following Table 2, The following compounds of Examples 70 to 73 were prepared from the amine D6 and the corresponding alkyl chloride by the procedure of Example 1. Example 70 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-benzylamine. Nmr (CDCl₃): 1.55-2.0(m,2H); 2.28(s,3H); 2.3-2.9(m,6H), 3.35(A(J=7Hz),2H); 3.74(s,3H); 3.78(s,3H); 4.44(s,2H); 6.1-6.45(m,2H), 7.74(d(J=8.5Hz), 1H); 7.0-7.5(m,10H). Example 71 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-2-nitrobenzylamine Nmr (CDCl₃): 1.55-2.05(m,2H); 2.30(s,3H); 2.35-2.9(m,6H); 3.34(A(J=7.2Hz),2H); 3.74(s,3H); 3.78(s,3H); 4.80(s,2H); 6.05-6.4(m,2H); 6.72(d(J=8.6Hz), 1H); 7.05-7.7(m,8H); 7.95-8.15(m,1H). Example 72 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-3-nitrobenzylamine Nmr (CDCl₃): 1.6-2.0(m,2H); 2.28(s,3H); 2.3-2.95(m,6H); 3.35(A(J=7.4Hz),2H); 3.76(s,3H); 3.78(s,3H); 4.48(s,2H); 6.1-6.4(m,2H); 6.72(d(J=8.6Hz), 1H), 7.0-7.65(m,7H); 7.9-8.2(m,1H). Example 73 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-(2-phenyl-ethyl)-N'-methyl-amino]-propyl)-4-nitrobenzylamine Nmr (CDCl₃): 1.5-2.0(m 2H); 2.29(s,3H); 2.3-2.95(m,6H); 3.2-3.5(m,2H); 3.75(s,3H); 3.78(s,3H); 4.50(s,2H); 6.05-6.4(m,2H); 6.73(d(J=8.8Hz),1H); 7.0-7.5(m,7H); 8.14(d(J=8.6Hz),2H). Example 74 (N-[3,4-Dimethoxyphenyl]-N-3-[N'-(2-phenyl-ethyl)-N'-methyl-amino]-propyl)-valeramide The title compound was prepared from amine D6 and pentanoic acid chloride by the procedure of Example 10. Nmr (CDCl₃): 0.82(A(J=6.2Hz),3H); 0.95-2.2(m,8H); 2.28(s,3H); 2.3-2.95(m,6H); 3.69(A(J=7.3Hz),2H); 3.86(s,3H); 3.90(s,3H); 6.55-6.95(m,3H); 7.0-7.5(m,5H). The structures of the compounds of Examples 70 to 74 are illustrated in the following Table 3: The following compounds of Examples 75 to 77 were prepared from amine D7 and the corresponding alkyl chloride by the procedure of Example 1. Example 75 (N-Phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methyl-amino]-propyl)-3-nitrobenzylamine Nmr (CDCl₃): 0.55-2.0(m,2H); 2.29(s,3H); 2.3-2.9(m,6H), 3.3-3.6(m,2H); 4.56(s,2H); 6.5-6.9(m,3H), 7.0-7.35(m,7H); 7.4-7.65(m,2H); 7.9-8.3(m,2H). Example 76 (N-Phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methyl-amino]-propyl)-4-nitrobenzylamine Nmr (CDCl₃): 1.55-2.0(m,2H); 2.29(s,3H); 2.3-3.0(m,6H), 3.3-3.6(m,2H); 4.57(s,2H); 6.5-6.9(m,3H); 7.0-7.5(m,9H), 8.14(d(J=8.6Hz),2H). Example 77 (N-Phenyl-N-3-[N'-(2-pnenyl-ethyl)-N'-methyl-amino]-propyl)-2-nitrobenzylamine Nmr (CDCl₃): 1.55-2.05(m,2H); 2.30(s,3H); 2.35-3.0(m,6H), 3.3-3.6(m,2H), 4.90(s,2H); 6.4-6.8(m,3H); 7.0-7.6(m,10H); 8.0-8.3(m,1H). Example 78 (N-Phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methyl-amino]-propyl)-valeramide The title compound was prepared from amine D7 and pentanoic acid chloride by the procedure of Example 10. Nmr (CDCl₃): 0.80(A(J=6.2Hz),3H); 0.95-2.2(m,8H); 2.24(s,3H); 2.3-2.9(m,6H), 3.72(A(J=7.3Hz),2H), 7.0-7.6(m,10H). The structures of the compounds of Examples 75 to 76 are illustrated in the following Table 4: Example 79 (N-(4-Chloro)phenyl-N-3-[N'-2-(3,4-dimethoxy-phenyl)-ethyl-N'-methyl-amino]-propyl)-4-nitrobenzamide hydrochloride The title compound was prepared from amine D8 and 4-nitrobenzoyl chloride by the procedure of Example 10. m.pt. 115 o C Nmr (CDCl₃): 2.1-2.6(m,2H); 2.83(d(J=4.5Hz) exch.D₂O s,3H); 2.95-3.5(m,6H); 3.85, 3.87, 4.02 (2s + t (J=6.5Hz),8H); 6.6-6.9(m,3H); 6.95-7.6(m,6H); 7.9-8.2(m,2H); 12.6 exch.D₂Os,1H). The compounds of Examples 1 to 51 and 57 to 78 are all oils in their free base form. PHARMACOLOGICAL DATA 1. Coronary Vasodilating activity a) Vasopressin test in anaesthetized rats Vasopressin (Lysopressin: 1 I.U./kg) was administered intravenously in order to provoke coronary spasm (ST-segment elevation in the ECG). Compound E1 was active against coronary spasm at a dose of 0.6g/kg i.d. The ability of test compounds to reduce coronary spasm is taken as a measure of their anti-anginal potential in spasm-induced angina pectoris. (Ref. Drug.Res. 33(11), 8,1117-1121 (1983)). b) Pig isolated coronary artery Coronary artery spirals were prepared and in lengths from 1.5 to 2 cm were incubated at 32.5 o in Ca⁺⁺-free Krebs-Henseleit solution containing tris buffer and 60 mM KCl. Ca⁺⁺ in concentrations ranging from 0.1 mM - 7 mM was given every 10 min to produce a control dose-response curve. Following a wash out circle using EDTA, either placebo or drug was administered, and an equilibration time of 30 minutes allowed before the second dose-response curve was made. Dose-ratios were calculated at ED₅₀-levels, from these the log K B was calculated. Compound E4 showed a log K B of 5.85, which indicates moderate to medium Ca⁺⁺-antagonistic activity in coronary artery in vitro . 2. Haemodynamic profile in anaesthetized rats . The effect of compounds of the invention on heart rate, systolic left ventricular pressure, left ventricular dp/dt max and mean arterial blood pressure was investigated so as to obtain information on the anti-anginal potential of these compounds, by reducing the oxygen demand of the ischaemic heart. Results are shown in Table 5. Results The above results demonstrate that the compounds of the invention have therapeutic potential in both stable and variant angina pectoris. Of special interest is the bradycardic activity without marked hypotension of the test compounds. Toxicity No toxic effects were observed in the above of the tests.

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing: wherein R₁ and R₄ are independently phenyl optionally substituted by one, two or three of halogen, trifluoromethyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, cyano, hydroxy, nitro, NR₅R₆ or O₂SNR₅R₆ wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl or together are C₃₋₆ polymethylene, or disubstituted at adjacent carbon atoms by C₁₋₂ alkylenedioxy and optionally further substituted by one of the above groups; R₂ is selected from (CH₂) z CN where z is O or an integer from 1 to 4 , C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl C₁₋₄ alkyl, pyridyl, pyridyl C₁₋₄ alkyl, COR₇, COCH₂COR₇, SO₂R₇, CO₂R₇, CONHR₇ and CSNHR₇, where R₇ is selected from C₃₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl and phenyl C₁₋₄ alkyl, any alkyl moiety in R₇ optionally substituted by hydroxy or C₁₋₄ alkanoyloxy, any pyridyl or phenyl moiety in R₂ optionally substituted as defined for R₁ and R₄ and any cycloalkyl moiety in R₂ optionally substituted by one or two C₁₋₄ alkyl groups; R₃ is hydrogen or C₁₋₄ alkyl; A represents C₂₋₅ alkylene; and B represents C₁₋₄ alkylene, for the preparation of a medicament for the treatment or prophylaxis of angina pectoris in mammals. A compound of formula (IA) which comprises a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing, with the proviso that the variables [R₁, R₂, A, R₃, B, R₄] do not take the following combinations of values: [phenyl, CO n C₃H₇, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, COiC₃H₇, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, COnC₃H₇, CH(CH₃)CH₂, CH₃, (CH₂)₂, phenyl] [phenyl, COnC₃H₇, CH₂CH(CH₃), CH₃, (CH₂)₂, phenyl] [phenyl, COiC₃H₇, CH₂CH(CH₃), CH₃, (CH₂)₂, phenyl] [phenyl, COnC₄H₉, CH₂CH(CH₃), CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₃, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, 4-chlorobenzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, 4-chlorophenyl] for use as an active therapeutic substance. A compound of formula (IA) as defined in claim 2 for the treatment or prophylaxis of angina pectoris. A pharmaceutical composition comprising a compound of formula (IA) as defined in claim 2 and a pharmaceutically acceptable carrier. A compound of formula (IB) which comprises a compound of formula (IA) as defined in claim 2 with the proviso that the variables [R₁, R₂, A, R₃, B, R₄] do not take the following combinations of values: [3,4-dimethoxyphenyl, C₂H₅, (CH₂)₂, H, (CH₂)₂, phenyl] [3,4-dimethoxyphenyl C₂H₅, (CH₂)₂, H, CH₂, phenyl] A compound according to claim 5, wherein R₁ and R₄ are independently phenyl substituted as defined in claim 1. A compound according to claim 5, wherein R₂ is COR₇ where R₇ is phenyl or phenyl C₁₋₄ alkyl, the phenyl moiety optionally substituted as defined for R₁ and R₄. A compound according to claim 5 of formula (IIa): wherein R₂² is COR₇ where R₇ is as defined in claim 5, and the remaining variables are as defined in claim 5. A compound according to claim 5 of formula (IIb): wherein R₂³ is CO₂R₇ or SO₂R₇ where R₇ is as defined in claim 5, and the remaining variables are as defined in claim 5. A compound according to claim 5 of formula (IIc): wherein R₂⁴ is CONHR₇ or CSNHR₇ where R₇ is as defined in claim 5, and the remaining variables are as defined in claim 5. A compound according to claim 5, wherein R₂ is C₃₋₁₂ alkyl. A compound according to claim 5 of formula (II): wherein: R₁, R₃ and R₄ are as defined in claim 7; and R₂¹ is (CH₂) z CN, C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl or phenyl C₁₋₄ alkyl wherein z is as defined in claim 5 and any phenyl, alkyl, or cycloalkyl moieties in R₂¹ are optionally substituted as defined for corresponding variables R₂ in claim 5. A compound according to claim 5, wherein R₁ and R₄ are independently phenyl substituted by one, two or three of halogen, trifluoromethyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, cyano, hydroxy, nitro, NR₅R₆ or O₂SNR₅R₆ wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl or together are C₃₋₆ polymethylene, or disubstituted at adjacent carbon atoms by C₁₋₂ alkylenedioxy; R₂ is selected from (CH₂) z CN where z is O or an integer from 1 to 4, C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl C₁₋₄ alkyl, COR₇, SO₂R₇, CO₂R₇, CONHR₇ and CSNHR₇, where R₇ is selected from C₃₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl and phenyl C₁₋₄ alkyl, any phenyl moiety in R₂ optionally substituted as defined for R₁ and R₄; R₃ is hydrogen or C₁₋₄ alkyl; A represents C₂₋₅ alkylene; and B represents C₁₋₄ alkylene. A compound according to any of claims 5 to 13 in which R₁ and R₄ are 3,4-dimethoxyphenyl. (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-cyanamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-cyanomethylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(3-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-methyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(3-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-butanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-methyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-pentanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-benzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-phenyl)-ethanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(3-phenyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-methyl)-phenylsulphonamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-dodecanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-octanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-hexanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-dodecanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-pentanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(2-methyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(3-phenyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3, 4-dimethoxyphenyl)-ethyl-N'methylamino]-propyl)-n-butylurethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-phenyl-urethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-n-butyl-urea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-n-propylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-i-propylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-t-butyl-urea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-benzylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-phenylurea, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl-N''-(1-phenyl)-ethyl-urea, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl-N''-n-propyl-urea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-n-pentylamine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]ethyl)-n-pentylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-3,5-dinitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-3-(3-methoxy-phenyl)-propylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-2,5-dimethyl-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-trifluoromethyl-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3-trifluoromethyl-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2,4,6-trimethyl-benzylamine, (N-[3,4-dimetnoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2,6-dichlorobenzyl-amine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-chloro-3,4-methylenedioxobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3,5-dinitro-2-amino-pyridine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-ethyl) -4-nitro-benzyl-amine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl) benzylamine. (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-ethyl) phenylacetamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl]-4-(4'-nitrophenyl)-butyramide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-nitrophenyl)-acetamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-N'-4-nitrobenzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-heptanamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-4-cyanobenzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N''-methyl-amino]-propyl)-4-trifluoromethylbenzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl]-3,5-dinitrobenzamide, (N-[3,4-dimethoxyphenyl]-N-3-(N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-4-chlorobenzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-(3-phenyl-2-acetoxy)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-N-4-nitrophenylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-hexyl-urethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-octyl-urethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-5-(-)-menthyl-urethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-cyclohexyl-amine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-isopropylamine, N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-hexylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-butylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino-propyl]-1-(3-oxo)-butyramide, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-4-nitro-benzylamine, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3-nitro-benzylamine, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-nitro-benzylamine, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-valeramide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenylethyl)-N'-methylamino]-propyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenylethyl)-N'-methylamino]-propyl)-2-nitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenyl- ethyl)-N'-methylamino]-propyl)-3-nitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenyl-ethyl)-N'-methyl-amino]-propyl)-4-nitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenylethyl)-N'-methyl-amino]-propyl)-valeramide, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-3-nitrobenzylamine, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-4-nitrobenzylamine, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-2-nitrobenzylamine, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-valeramide, (N-(4-chloro)phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-4-nitrobenzamide, or a pharmaceutically acceptable salt of any of the foregoing. A process for the preparation of a compound according to claim 5, which process comprises reacting together R₁₀X and YR₁₁ wherein one of X and Y is a leaving group or aldehyde or ketone function and the other is a nitrogen nucleophile, the nitrogen nucleophile, R₁₀ and R₁₁, and the aldehyde or ketone function when present, being such that a compound of formula (III) is formed: R₁-NR₂'A'-NR₃'-B'-R₄ (III) in which R₂', A', R₃' and B' are R₂, A, R₃ and B respectively or groups convertible thereto, and R₁, R₂, A, R₃, B and R₄ are as defined in claim 5, and thereafter, optionally or as necessary, converting R₂', A', R₃', and/or B' to R₂, A, R₃ and/or B, interconverting R₂ and/or R₃ and/or forming a pharmaceutically acceptable salt. 1-[N-Methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino]- propyl-3-(3,4-dimethoxy)-aniline, 1-[N-methyl-N-2-(3,4-dimethoxyphenyl)- ethylamino]-ethyl-2-(3,4-dimethoxy)-aniline, 1-[N-methyl-N-2-(3,4-dimethoxyphenyl)- ethylamino]-propyl-3-aniline, 1-[N-methyl-N-2-phenylethylamino]propyl- 3-(3,4-dimethoxy)-aniline or 1-[N-methyl-N-2-(3,4-dimethoxyphenyl)-ethylamino]-propyl-3-(4-chloro)-aniline. Claims for the following Contracting State : ES The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing: wherein R₁ and R₄ are independently phenyl optionally substituted by one, two or three of halogen, trifluoromethyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, cyano, hydroxy, nitro, NR₅R₆ or O₂SNR₅R₆ wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl or together are C₃₋₆ polymethylene, or disubstituted at adjacent carbon atoms by C₁₋₂ alkylenedioxy and optionally further substituted by one of the above groups; R₂ is selected from (CH₂) z CN where z is O or an integer from 1 to 4 , C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl C₁₋₄ alkyl, pyridyl, pyridyl C₁₋₄ alkyl, COR₇, COCH₂COR₇, SO₂R₇, CO₂R₇, CONHR₇ and CSNHR₇, where R₇ is selected from C₃₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl and phenyl C₁₋₄ alkyl, any alkyl moiety in R₇ optionally substituted by hydroxy or C₁₋₄ alkanoyloxy, any pyridyl or phenyl moiety in R₂ optionally substituted as defined for R₁ and R₄ and any cycloalkyl moiety in R₂ optionally substituted by one or two C₁₋₄ alkyl groups; R₃ is hydrogen or C₁₋₄ alkyl; A represents C₂₋₅ alkylene; and B represents C₁₋₄ alkylene, for the preparation of a medicament for the treatment or prophylaxis of angina pectoris in mammals. A process for the preparation of a compound of formula (IB) which comprises a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing, with the proviso that the variables [R₁, R₂, A, R₃, B, R₄] do not take the following combinations of values: [phenyl, CO n C₃H₇, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, COiC₃H₇, (CH₂)₂, CH₃ CH₂, phenyl] [phenyl, COnC₃H₇, CH(CH₃)CH₂, CH₃, (CH₂)₂, phenyl] [phenyl, COnC₃H₇, CH₂CH(CH₃), CH₃, (CH₂)₂, phenyl] [phenyl, COiC₃H₇, CH₂CH(CH₃), CH₃, (CH₂)₂, phenyl] [phenyl, COnC₄H₉, CH₂CH(CH₃), CH₃,(CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, CH₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₃, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, H, (CH₂)₂, phenyl] [4-chlorophenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, 4-chlorobenzyl, (CH₂)₂, CH₃, (CH₂)₂, phenyl] [phenyl, benzyl, (CH₂)₂, CH₃, (CH₂)₂, 4-chlorophenyl] [3,4-dimethoxyphenyl, C₂H₅, (CH₂)₂, H, (CH₂)₂, phenyl] [3,4-dimethoxyphenyl, C₂H₅, (CH₂)₂, H, CH₂, phenyl], which process comprises reacting together R₁₀X and YR₁₁ wherein one of X and Y is a leaving group or aldehyde or ketone function and the other is a nitrogen nucleophile, the nitrogen nucleophile, R₁₀ and R₁₁, and the aldehyde or ketone function when present, being such that a compound of formula (III) is formed: R₁-NR₂'-A'-NR₃'-B'-R₄ (III) in which R₂' A', R₃' and B' are R₂, A, R₃ and B respectively or groups convertible thereto, and R₁, R₂, A, R₃, B and R₄ are as defined in claim 1, and thereafter, optionally or as necessary, converting R₂', A', R₃', and/or B' to R₂, A, R₃ and/or B, interconverting R₂ and/or R₃ and/or forming a pharmaceutically acceptable salt. A process according to claim 2, wherein R₁ and R₄ are independently phenyl substituted as defined in claim 1. A process according to claim 2, wherein R₂ is COR₇ where R₇ is phenyl or phenyl C₁₋₄ alkyl, the phenyl moiety optionally substituted as defined for R₁ and R₄. A process according to claim 2 for preparing a compound of formula (IIa): wherein R₂² is COR₇ where R₇ is as defined in claim 2, and the remaining variables are as defined in claim 2. A process according to claim 2 for preparing a compound of formula (IIb): wherein R₂³ is CO₂R₇ or SO₂R₇ where R₇ is as defined in claim 2, and the remaining variables are as defined in claim 2. A process according to claim 2 for preparing a compound of formula (IIc): wherein R₂⁴ is CONHR₇ or CSNHR₇ where R₇ is as defined in claim 2, and the remaining variables are as defined in claim 2. A process according to claim 2, wherein R₂ is C₃₋₁₂ alkyl. A process according to claim 2 for preparing a compound of formula (II): wherein: R₁, R₃ and R₄ are as defined in claim 4; and R₂¹ is (CN₂) z CN, C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl or phenyl C₁₋₄ alkyl wherein z is as defined in claim 2 and any phenyl, alkyl, or cycloalkyl moieties in R₂¹ are optionally substituted as defined for corresponding variables R₂ in claim 2. A process according to claim 2, wherein R₁ and R₄ are independently phenyl substituted by one, two or three of halogen, trifluoromethyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, cyano, hydroxy, nitro, NR₅R₆ or O₂SNR₅R₆ wherein R₅ and R₆ are independently hydrogen or C₁₋₆ alkyl or together are C₃₋₆ polymethylene, or disubstituted at adjacent carbon atoms by C₁₋₂ alkylenedioxy; R₂ is selected from (CH₂) z CN where z is O or an integer from 1 to 4, C₁₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl C₁₋₄ alkyl, COR₇, SO₂R₇, CO₂R₇, CONHR₇ and CSNHR₇, where R₇ is selected from C₃₋₁₂ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, phenyl and phenyl C₁₋₄ alxyl, any phenyl moiety in R₂ optionally substituted as defined for R₁ and R₄; R₃ is hydrogen or C₁₋₄ alkyl; A represents C₂₋₅ alkylene; and B represents C₁₋₄ alkylene. A process according to any of claims 2 to 10 in which R₁ and R₄ are 3,4-dimethoxyphenyl. A process according to claim 2 for preparing (N-[3,4-Dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-cyanamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-cyanomethylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3'4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(3-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-methyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(3-nitro)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-butanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-methyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-pentanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-benzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(2-phenyl)-ethanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(3-phenyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-methyl)-phenylsulphonamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-dodecanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-octanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-hexanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-dodecanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-pentanoic acid amide, (M-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(2-methyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl)-(3-phenyl)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3, 4-dimethoxyphenyl)-ethyl-N'methylamino]-propyl)-n-butylurethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-phenyl-urethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-n-butyl-urea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-n-propylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-i-propylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-t-butyl-urea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-benzylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-N''-phenylurea, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl-N''-(1-phenyl)-ethyl-urea, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl-N''-n-propyl-urea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-n-pentylamine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]ethyl)-n-pentylamine, (N-[3,4-dimethoxypnenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-3,5-dinitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-3-(3-methoxy-phenyl)-propylamine, (N-[3,4-dimetoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-2,5-dimethyl-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-trifluoromethyl-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3-trifluoromethyl-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2,4,6-trimethyl-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2,6-dichlorobenzyl-amine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-chloro-3,4-methylenedioxobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3,5-dinitro-2-amino-pyridine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-ethyl) -4-nitro-benzyl-amine, (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-ethyl) benzylamine. (N-[3,4-dimethoxyphenyl]-N-2-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-ethyl) phenylacetamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl]-4-(4'-nitrophenyl)-butyramide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-(4-nitrophenyl)-acetamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-N'-4-nitrobenzamide, (M-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-heptanamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-4-cyanobenzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-4-trifluoromethylbenzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl]-3,5-dinitrobenzamide, (N-[3,4-dimethoxyphenyl]-N-3-(N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-4-chlorobenzamide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-(3-phenyl-2-acetoxy)-propanoic acid amide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-N-4-nitrophenylurea, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-hexyl-urethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-n-octyl-urethane, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-5-(-)-menthyl-urethane, (N-[3,4-dimethoxypnenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-cyclohexyl-amine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-isopropylamine, N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-hexylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino]-propyl)-butylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methylamino-propyl]-1-(3-oxo)-butyramide, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-metnyl-amino]-propyl)-4-nitro-benzylamine, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-3-nitro-benzylamine, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-2-nitro-benzylamine, (N-phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-valeramide, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenylethyl)-N'-methylamino]-propyl)-benzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenylethyl)-N'-methylamino]-propyl)-2-nitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenyl- ethyl)-N'-methylamino]-propyl)-3-nitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenyl-ethyl)-N'-methyl-amino]-propyl)-4-nitrobenzylamine, (N-[3,4-dimethoxyphenyl]-N-3-[N'-(2-phenylethyl)-N'-methyl-amino]-propyl)-valeramide, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-3-nitrobenzylamine, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-4-nitrobenzylamine, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-2-nitrobenzylamine, (N-phenyl-N-3-[N'-(2-phenyl-ethyl)-N'-methylamino]-propyl)-valeramide, (N-(4-chloro)phenyl-N-3-[N'-2-(3,4-dimethoxyphenyl)-ethyl-N'-methyl-amino]-propyl)-4-nitrobenzamide, or a pharmacutically acceptable salt of any of the foregoing.

Inventors: MASCHLER, HARALD
Applicants: BEECHAM - WUELFING GMBH & CO. KG
Application year: 1987
Main classification: A61K31
IPC codes: A61P9, C07C261, C07C325, C07C269, C07D213, C07C209, A61K31, C07C213, C07C253, C07C311, C07C335, C07C235, C07C301, C07C217, C07D317, C07C275, C07C211, C07C233, C07C67, A61P3, C07C255, C07C231, C07C239, C07C237